Vaxcyte, Inc. (PCVX): Total Liabilities
$317.21M
As of 2025-12-31
$380.21M
As of 2026-06-30
+82.1%
3-year compound annual growth
+46.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $317.21M | +54.4% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $205.50M | +22.7% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $167.45M | +218.6% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $52.56M | +30.4% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $40.32M | -14.2% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $46.98M | +299.5% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $11.76M | n/a | 2021-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | 2025-12-31 | $317.21M | +54.4% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $683.10M | -2.9% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.48B | +45.7% |
| Revolution Medicines, Inc. (RVMD) | 2025-12-31 | $723.21M | +146.7% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $343.43M | +10.8% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.38B | +22.1% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $163.15M | +14.6% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $242.82M | -34.4% |
Compare PCVX, RGEN, EXEL, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗